6.4 Post-translational modifications of proteins

Types of Protein Modifications

Proteins fresh off the ribosome aren't necessarily ready to work. They undergo post-translational modifications (PTMs), chemical changes that alter a protein's structure, function, and interactions. PTMs let cells fine-tune protein behavior rapidly, without having to transcribe and translate entirely new proteins.

Chemical Alterations and Attachments

Each type of PTM involves attaching a specific chemical group to particular amino acid residues:

• Phosphorylation adds a phosphate group (from ATP) to serine, threonine, or tyrosine residues. This is the most common reversible PTM and plays a central role in signaling.
• Glycosylation attaches sugar chains to proteins. N-linked glycosylation occurs on asparagine residues (begins co-translationally in the ER), while O-linked glycosylation occurs on serine or threonine residues (post-translationally, often in the Golgi).
• Ubiquitination covalently attaches the small protein ubiquitin to lysine residues, most famously tagging proteins for degradation by the proteasome.
• Acetylation adds an acetyl group to lysine residues. Histone acetylation, for instance, loosens chromatin and promotes gene expression.
• Methylation transfers methyl groups to lysine or arginine residues. On histones, methylation can either activate or repress transcription depending on which residue is modified.
• SUMOylation attaches a small ubiquitin-like modifier (SUMO) protein, often regulating nuclear transport and transcription factor activity.

Impact on Protein Structure and Function

PTMs change how a protein behaves in several ways:

• Conformational changes. Adding a charged phosphate group, for example, can shift a protein's 3D shape enough to activate or inactivate its catalytic site.
• Binding site creation or masking. A PTM can expose a new surface that other proteins recognize, or block an existing interaction site.
• Stability and lifespan. Glycosylation often stabilizes extracellular proteins, while polyubiquitination marks proteins for proteasomal degradation.
• Localization. Some modifications direct proteins to specific compartments. Glycosylation helps route proteins through the secretory pathway; other PTMs can add or reveal nuclear localization signals.

A single protein can carry multiple different PTMs simultaneously. The specific combination creates what's sometimes called a "PTM code", where the overall pattern of modifications determines the protein's net behavior. Histone proteins are the classic example: dozens of acetylation, methylation, and phosphorylation marks combine to regulate chromatin state and gene expression.

Regulation of Protein Function

Molecular Switches and Interactions

Reversible PTMs act as molecular switches. Phosphorylation is the best example: a kinase adds a phosphate group to activate (or inactivate) a protein, and a phosphatase removes it, returning the protein to its original state. This happens in seconds, far faster than making new protein.

These switches control protein-protein interactions with high specificity. In signal transduction, phosphorylated tyrosine residues on receptor tyrosine kinases create docking sites for proteins containing SH2 domains. Only the right combination of phosphorylation and domain recognition allows the interaction, keeping signaling precise.

Signal Transduction and Cellular Response

PTMs are the backbone of signal transduction. Consider the MAPK cascade: an extracellular signal triggers sequential phosphorylation of kinases (Raf → MEK → ERK), amplifying the signal at each step and ultimately changing gene expression. The entire cascade relies on PTMs rather than new protein synthesis, which is why cells can respond to stimuli within minutes.

The combination of multiple PTMs across many proteins allows cells to integrate different signals simultaneously. Stress response pathways, growth factor signaling, and metabolic regulation all depend on this rapid, reversible PTM-based logic.

Mechanisms of Common Modifications

Enzymatic Processes

Phosphorylation

1. A protein kinase binds its target protein and recognizes a specific sequence or structural motif around the target residue (serine, threonine, or tyrosine).
2. The kinase transfers the terminal phosphate group from ATP to the hydroxyl group of that residue.
3. To reverse the modification, a protein phosphatase hydrolyzes the phosphate group off.

Cyclin-dependent kinases (CDKs) are a key example: they phosphorylate specific substrates at each stage of the cell cycle, driving progression from one phase to the next.

Glycosylation

1. N-linked glycosylation begins in the ER, where an oligosaccharyltransferase transfers a preassembled sugar tree (14 sugars) to an asparagine residue within the consensus sequence Asn-X-Ser/Thr (where X is any amino acid except proline). This happens co-translationally as the polypeptide enters the ER lumen.
2. The sugar chain is then trimmed and further modified as the protein moves through the ER and Golgi.
3. O-linked glycosylation occurs later, primarily in the Golgi, where glycosyltransferases add sugars one at a time to serine or threonine residues.

Mucin glycoproteins, which are heavily O-glycosylated, form the protective mucus layer lining the gut and respiratory tract.

Ubiquitination

1. An E1 activating enzyme uses ATP to activate ubiquitin and attach it to itself via a thioester bond.
2. Ubiquitin is transferred to an E2 conjugating enzyme.
3. An E3 ubiquitin ligase brings the E2 and the target protein together, catalyzing transfer of ubiquitin to a lysine residue on the substrate. The E3 ligase determines substrate specificity.
4. Repeated rounds build a polyubiquitin chain, which is recognized by the 26S proteasome for degradation.
5. Deubiquitinating enzymes (DUBs) can remove ubiquitin, adding another layer of regulation.

A classic example: cyclins are ubiquitinated and degraded at specific cell cycle checkpoints, ensuring the cell doesn't re-enter a phase prematurely.

Specificity and Reversibility

Two features make PTMs effective regulators:

• Specificity. Modifying enzymes recognize particular amino acid sequences or structural motifs on their substrates. An E3 ligase, for instance, won't ubiquitinate just any protein; it binds a defined set of targets.
• Reversibility. Most major PTMs have dedicated "eraser" enzymes (phosphatases, deubiquitinases, deacetylases). This means the modification can be toggled on and off as conditions change.

Together, specificity and reversibility allow precise, dynamic control. In glucose metabolism, for example, phosphorylation and dephosphorylation of glycogen synthase and glycogen phosphorylase rapidly shift the cell between glycogen synthesis and breakdown depending on insulin and glucagon signaling.

Importance in Cellular Processes and Disease

Physiological Roles

PTMs regulate nearly every major cellular process:

• Cell division. Phosphorylation cascades driven by CDKs control cell cycle progression. Ubiquitination of cyclins ensures orderly phase transitions.
• Cell signaling. Growth factor binding triggers receptor autophosphorylation, recruiting downstream signaling proteins. G-protein coupled receptor signaling also depends on phosphorylation for receptor desensitization.
• Protein trafficking. Glycosylation in the ER and Golgi helps proteins fold correctly and routes them to the cell surface, lysosomes, or secretory vesicles. Mannose-6-phosphate tags, for instance, direct lysosomal enzymes to the lysosome.
• Gene regulation. Histone PTMs (acetylation, methylation, phosphorylation) control chromatin accessibility and transcription.

Disease Implications and Therapeutic Targets

When PTM regulation goes wrong, disease often follows:

• Cancer. Mutations in kinases can lock them in an "always on" state. EGFR mutations in non-small cell lung cancer cause constitutive signaling for cell growth. Cancer cells also display altered glycosylation profiles on their surface, which can affect cell adhesion and immune evasion.
• Neurodegenerative disease. Defects in the ubiquitin-proteasome system lead to accumulation of misfolded protein aggregates. In Parkinson's disease, mutations in the E3 ligase Parkin impair clearance of damaged mitochondrial proteins. Hyperphosphorylation of tau protein is a hallmark of Alzheimer's disease.
• Therapeutic targeting. Because PTM enzymes are often druggable, they're major pharmaceutical targets. Imatinib (Gleevec) inhibits the BCR-ABL fusion kinase in chronic myeloid leukemia and was one of the first successful targeted cancer therapies. Proteasome inhibitors like bortezomib treat multiple myeloma by blocking ubiquitin-dependent protein degradation.

Understanding PTM dysregulation also helps identify biomarkers for diagnosis. Abnormal phosphorylation or glycosylation patterns in patient samples can signal specific cancers or disease states, guiding treatment decisions.